AI English summary of an SEC filing — figures as filed
Gilead Sciences GILDGilead Sciences said that on Q2 2026 total revenues were $7.8 billion, up 10% year-over-year, and diluted loss per share was $(8.45), compared with diluted earnings per share of $1.56 in the same period in the prior year. The company cited the $(9.08) per share impact of acquired in-process research and development expenses as the primary driver of the loss per share.
Key points
AI summaryGilead Sciences said that on Q2 2026 total revenues were $7.8 billion, up 10% year-over-year, and diluted loss per share was $(8.45), compared with diluted earnings per share of $1.56 in the same period in the prior year. The company cited the $(9.08) per share impact of acquired in-process research and development expenses as the primary driver of the loss per share.
Gilead said that on Q2 2026 HIV product sales were $5.7 billion, up 12% year-over-year, Biktarvy sales were $3.8 billion, up 7%, and Descovy sales were $967 million, up 48%. Veklury sales were $23 million, down 81%.
The company said that on Q2 2026 acquired in-process research and development expenses were $11.2 billion, primarily related to $7.0 billion for the Arcellx acquisition, $3.1 billion for the Tubulis acquisition and $1.0 billion for the Ouro Medicines acquisition, net of the impact of the Lakefront collaboration.
Gilead said that as of June 30, 2026 it had $3.2 billion of cash, cash equivalents and marketable debt securities, compared with $10.6 billion as of December 31, 2025. It cited year-to-date cash outflows of $11.3 billion related to acquisitions as a decrease factor, and said that during Q2 it generated $3.6 billion in operating cash flow.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 2026 Revenues $7.8 billion, Loss Per Share $(8.45)
Gilead Sciences said that on Q2 2026 total revenues were $7.8 billion, up 10% year-over-year, and diluted loss per share was $(8.45), compared with diluted earnings per share of $1.56 in the same period in the prior year. The company cited the $(9.08) per share impact of acquired in-process research and development expenses as the primary driver of the loss per share.
Source · Based on the filing body and exhibits
Q2 Product Sales: HIV $5.7 billion, Veklury $23 million
Gilead said that on Q2 2026 HIV product sales were $5.7 billion, up 12% year-over-year, Biktarvy sales were $3.8 billion, up 7%, and Descovy sales were $967 million, up 48%. Veklury sales were $23 million, down 81%.
Source · Based on the filing body and exhibits
Q2 Acquired In-Process Research and Development Expenses $11.2 billion
The company said that on Q2 2026 acquired in-process research and development expenses were $11.2 billion, primarily related to $7.0 billion for the Arcellx acquisition, $3.1 billion for the Tubulis acquisition and $1.0 billion for the Ouro Medicines acquisition, net of the impact of the Lakefront collaboration.
Source · Based on the filing body and exhibits
June 30, 2026 Cash and Q2 Operating Cash Flow
Gilead said that as of June 30, 2026 it had $3.2 billion of cash, cash equivalents and marketable debt securities, compared with $10.6 billion as of December 31, 2025. It cited year-to-date cash outflows of $11.3 billion related to acquisitions as a decrease factor, and said that during Q2 it generated $3.6 billion in operating cash flow.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…